Skip to main content
SpringerLink
Log in

Orbofiban: higher risk of thrombocytopenia

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Scirica BM, Cannon CP, Cooper R, Aster RH, Brassard J, McCabe CH, Charlesworth A, Skene AM, Braunwald E.Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes-(OPUS-TIMI 16) trial. Journal of Thrombosis and Thrombolysis 22: 95-102, No. 2, Oct 2006

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Orbofiban: higher risk of thrombocytopenia. React. Wkly. 1129, 1 (2006). https://doi.org/10.2165/00128415-200611290-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200611290-00001

Keywords

Search

Navigation